Overview

Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3 study comparing the efficacy, safety and tolerability of moxidectin and ivermectin in subjects infected with Onchocerca volvulus, which is the parasite that causes river blindness. Subjects participating in the study will be randomly assigned (by a 2 to1 ratio) to receive one orally-administered dose of either moxidectin or ivermectin.
Phase:
Phase 3
Details
Lead Sponsor:
Medicines Development for Global Health
World Health Organization
Collaborator:
World Health Organization
Treatments:
Ivermectin
Milbemycin
Moxidectin